Open AccessLong-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib
Author(s) -
Emad Mohsen Barsoum,
Mahmoud Mohammed Ahmed El-Demery,
Nada Osman,
May Gamal Ashour,
Mohsen Samy Barsoum
Publication year - 2021
Publication title -
journal of medical cases
Language(s) - English
Resource type - Journals
eISSN - 1923-4163
pISSN - 1923-4155
DOI - 10.14740/jmc3743
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , lung cancer , oncology , alk inhibitor , lymphoma , progression free survival , chemotherapy , malignant pleural effusion
Lung cancer is the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase ( ALK ) gene rearrangements constitutes 3-5%. Crizotinib was approved for the first-line therapy of advanced ALK-positive NSCLC patients. We present a female patient with advanced ALK-positive NSCLC who was kept on crizotinib as first-line therapy and showed progression-free survival (PFS) of 48 months despite the data suggesting that the majority of patients on crizotinib show relapse within 1 year. Further studies should focus on the molecular and biological factors and the possible effect of the long-term use of this drug.